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Abstract: 
 
The tetrameric composition of human hemoglobin complicates protein engineering efforts 
that are required to improve its potential as an oxygen-carrying therapeutic. In our research to 
design a single-chain version of the hemoglobin molecule (scHb), we have co-expressed a 
circularly permuted human β-globin (cp-β) with human -globin. At micromolar 
concentrations, the purified recombinant globins appear to associate to form an -cpβ 
heterodimer in solution rather than the expected 2-cpβ2 heterotetramer. Compared to 
recombinant human hemoglobin, the -cpβ heterodimer exhibits a stronger ligand binding 
affinity. Knowledge of the intermolecular interactions favoring formation of the -cpβ 
heterodimer will be instrumental in understanding the global structural consequences of the 
cpβ mutation, and in directing future protein engineering efforts to optimize the function of 
permuted hemoglobins. X-ray diffraction of -cpβ crystals has been employed to determine 
the molecular structure of this protein complex at near-atomic resolution (2.7 Å). 
Examination of the structure shows that, in the crystal, the subunits associate to form a 
heterotetramer similar to that of wild-type hemoglobin in the high affinity “R-state”. The 
structure also confirms the incorporation of the β-globin His146 (wild-type numbering) into 
the cpβ linker, which removes an important ionic interaction that stabilizes the low oxygen 
affinity (T state) conformation. Structural information obtained as a result of this work will 
guide future protein engineering efforts to enhance cooperativity of oxygen binding and the 
T-state stability of future hemoglobin constructs.  
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Introduction: 
 
The American Association of Blood Banks has predicted an acute shortage of packed red 
blood cells (RBCs) by 2030 as demand for blood is expected to surpass the rate at which it 
can be supplied [1] if trends continue as illustrated in Figure 1. This will increase the cost of 
medical procedures and prevent patients from receiving life-saving transfusions. In an 
attempt to mitigate the detrimental effects of a blood shortage, and reduce instances of 
adverse reactions to transfusions (Figure 2), efforts are underway in many labs to develop 
hemoglobin-based blood substitutes to augment the supply of donor-derived blood.  
 
Figure 1. Whole blood and red blood cell transfusions and donations from 1989-2004. 
Available collections represent those units that have been approved for administration [1]. 
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Figure 2. Adverse reactions from transfusions 2006-2008 in the US [2]. 
 
Many approaches have been taken to develop a blood replacement, unfortunately none of 
these emerging therapeutics has been proven sufficiently safe or effective to supplement the 
donor-derived blood supply. We believe that our approach to developing a hemoglobin-based 
blood substitute will aid efforts to develop a safe, effective, and economically viable blood 
replacement therapy. A long standing goal of many in private and public enterprise has been 
the development of a cell-free hemoglobin-based oxygen carrier (HBOC) that can be readily 
manufactured in large quantities, is stable, and has functional properties equal to or 
exceeding those of red blood cells. HBOCs are excellent candidates to fill the gap between 
the supply and demand for blood because they are derived from a naturally-occurring oxygen 
transporter. Representative HBOCs are illustrated in Figure 3.  
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Figure 3. Hemoglobin-based oxygen carriers [3] 
 
Native human hemoglobin is a soluble globular heme-protein composed of four subunits: two 
α- and two β-globins. Heme is a tetrapyrrole porphyrin macrocycle that coordinates an iron 
ion and enables each globin subunit to bind an oxygen ligand. The globins are composed 
primarily of α-helices, with 8 helices per β-globin (denoted A-H) and 7 homologous helices 
per α-globin (denoted A-C and E-H). These globin subunits spontaneously associate into αβ-
heterodimers, through the formation of inter-subunit hydrogen bonds and salt-bridges. Two 
αβ–heterodimers associate to form the α2β2 heterotetramer (i.e., native hemoglobin is a dimer 
of heterodimers). Interactions between the two associated heterodimers enable hemoglobin to 
bind oxygen cooperatively, a function that is essential for efficient oxygen transport. Figure 4 
illustrates the oxygen binding affinity profiles for a variety of HBOCs; αα-crosslinked Hb is 
the only HBOC with a profile similar to that of human red blood cells [4].  
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Figure 4. Oxygen dissociation curves for various HBOCs. Curves are shown for human red 
blood cells, an αα cross-linked Hb (a covalently cross-linked HBOC generated by 
recombinant DNA technology), and other oxygen carrying therapeutics based on chemical 
modification of native hemoglobin [4].  
 
Hemoglobin’s oxygen binding cooperativity is mediated by the allosteric shift that occurs 
upon binding an oxygen ligand to the low oxygen affinity, or deoxy-Hb, conformation. 
Oxygen binding to the heme iron induces strain, which is relieved by movement of the F-
helix and the associated remodeling of the interface between the /β heterodimers. These 
structural shifts induce strain in adjacent globin subunits, which favors a global change in the 
conformation of the hemoglobin tetramer into the high oxygen binding affinity, or R state, 
conformation. When oxygen concentrations are lowered, these structural shifts are reversed, 
oxygen ligands are released, and all subunits cooperatively return to the lower affinity state. 
This mechanism enables efficient oxygen transport between areas of high and low oxygen 
concentration. The R and T states, illustrated in Figure 5, are characterized by changes in the 
relative orientations between of the two αβ-heterodimers.  
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Figure 5. Cartoon diagram of the deoxy- “T” and oxy- “R” states of hemoglobin. The ligand 
binding heme subunit is denoted in red and encircled by a black ring at the center of each 
diagram. An oxygen molecule can be seen bound to the heme ligand in the oxy-hemoglobin 
diagram. From [5], used without permission. 
 
Direct administration of wild type hemoglobin (wtHb) as a therapeutic would be the simplest 
method to restore oxygen-carrying capacity, unfortunately wtHb cannot be used directly as a 
cell-free therapeutic due to toxic side effects. Cell-free Hb exhibits significantly lower 
stability compared to Hb contained within erythrocytes (red blood cells, or RBCs). Outside 
of RBCs the Hb tetramer dissociates into αβ-heterodimers, which are small enough to be 
filtered by the kidneys, where the subsequent release of heme in unnaturally high amounts 
[6] causes renal failure. Additionally, cell-free oxy-hemoglobin scavenges nitric oxide (NO), 
a potent vasodilator, resulting in increased in blood pressure through arterial smooth muscle 
contraction. 
 
Renal toxicity can be ameliorated by preventing the dissociation of the 64 kDa 
heterotetramer into 32 kDa heterodimers. The rHb1.1 molecule, illustrated in Figure 6, 
showed no renal toxicity in Phase I and II safety trials, and is no larger than wt Hb [7], [8]. It 
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has also been reported that larger oligomeric Hbs exhibit reduced blood pressure elevation 
(“vasoactivity” or “pressor response”), which is a significant undesirable side effect [8] (see 
Figures 7 and 8). Work in our lab is aimed at addressing the vasoactivity of cell-free Hb 
through protein engineering. Specifically, we have covalently linked the four globin subunits 
to make a hemoglobin composed of a single polypeptide chain (single-chain hemoglobin or 
scHb). We plan to generate polymeric hemoglobins of defined molecular weight using the 
scHb as a protomer. We hypothesize that such engineered HBOCs will exhibit a reduction in 
pressor response and enhancement in therapeutic value as was observed for 130 kDa and 260 
kDa recombinant hemoglobins developed by Somatogen [8].  
 
 
 
Figure 6. Previous work performed at Somatogen to increase the size of hemoglobin through 
covalent linkages [8]. Red circles with ‘α’ symbol represent α-globins, blue circles with ‘β’ 
represent β-globins, colored lines connecting circles represent covalent linkages, and ‘HS-‘ 
represents the addition of a reactive thiol moiety by mutation of lysine 457 to cysteine.  
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Figure 7. Change in peritoneal hemoglobin concentration as a function of time and size of 
hemoglobin molecule. Open bars are for a 64 kDa hemoglobin and the filled bars are for a 
130 kDa polymeric hemoglobin [8]. 
 
 
 
Figure 8. Change in mean arterial pressure (MAP) in conscious rats following intravenous 
injection of human serum albumin (purple squares), a 64 kDa hemoglobin (orange triangles), 
a 130 kDa polymeric hemoglobin (blue circles), or a 260 kDa polymeric hemoglobin (green 
cross) [8]. 
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Development of a scHb will require covalent linkage of the α- & β-globin subunits within a 
single heterodimer and covalent linkage between the αβ-heterodimers across the dimer 
interface as illustrated in Figure 9. During the shift from the deoxy (“T”) to the oxy (“R”) 
state, these heterodimers rotate by 15° with respect to one another across the α1β2 interface of 
the tetramer, while the α1β1 interface between globins within a heterodimer remains relatively 
static. Our scHb design creates covalent connections across the α1β1 and α1β2 interfaces to 
minimize interference with allosteric switching of the tetramer. Linkage between 
heterodimers will be carried out as in rHb1.1, where the α1-globin and α2-globin are 
covalently linked with a single glycine residue (Figure 10). 
 
 
Figure 9. Illustration of the α1β1 interface within a heterodimer (green) and the α1β2 
interface between heterodimers (orange). α-globins are in red and β-globins are in blue. 
 
Covalent linkage within a heterodimer is considerably more challenging due to the relatively 
large distance between the α- & β-globin termini, approximately 50 Å through the center of 
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the wtHb tetramer, as illustrated in Figure 10. Linking the α1- & β2-globin termini in this 
manner would require a very long linker that would have to go around the outside of the 
molecule; this large modification at the interface of the heterodimers could negatively impact 
the folding and stability of the protein.  
 
 
Figure 10. Illustration of the distances between the termini of the α1- & α2-globins (orange 
oval) and the termini of the α1- & β1-globins (green rectangle). Red circles are α-globins, the 
blue circles are β-globins, and short lines represent polypeptide termini for each globin. 
 
The T-state conformation is dependent upon the formation of stabilizing interactions between 
the two αβ-heterodimers. Thus, the α1β2 interface must be maintained in the design of the 
scHb. Our protein engineering efforts are targeted at designing a single-chain α1β1 
heterodimer, which can self-associate to form a sc-Hb. Covalent linkage via the insertion of a 
long linker between the α1- and β1-termini would likely enhance immunogenicity, and be a 
substrate for serum proteases due to its solvent-accessibility and flexible structure (dictated 
by the need to connect the native termini while minimally perturbing the R ↔ T switching of 
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the tetrameric structure). Relocation of the β-termini (the α-termini already tolerate covalent 
linkage as shown by rHb1.1) was identified as an alternative approach for covalent fusion of 
globins across the α1β1 interface [9].  
 
Circular permutation is the process by which existing protein termini can be relocated to an 
alternative site in a protein, as illustrated in Figure 11. We used circular permutation to 
relocate the β-globin termini. The site for insertion of new β-globin termini was chosen for 
its relative proximity to an external loop on the adjacent α-globin. As illustrated in Figure 12, 
this site in the loop between the β-globin G- and H-helices was selected for covalent linkage 
of the α- and β-globins, because it is close to the α1β1 interface, and a similar permutation 
was well tolerated in myoglobin, which is a structural homologue of the Hb β-globin subunit 
[10]. Native β-globin termini were successfully fused by insertion of an eight amino acid 
linker (GSGGQGGG) and new termini were inserted via primer extension of a tandem β–
globin gene to form a circularly permuted (cp) β-globin (cpβ) [11]  
 
Figure 11. Illustration of the process of circular permutation of the β-globin. N & C identify 
the amino (N) and carboxyl (C) termini, respectively. The letters A-H represent helices A-H, 
and the yellow curve represents the inserted linker. 
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Figure 12. Illustration of the external loops of the α1- (orange) & β1-globins (green) and their 
relative proximity. α-Globins are in red and β-globins are in blue. 
 
Recombinant α-globin and cpβ-globin (Figure 13) were co-expressed in E. coli, purified, and 
characterized structurally and functionally [11]. These subunits spontaneously associated to 
form α-cpβ heterodimers at low concentration, ~5 μM, which in-turn dimerized into an 
α2(cpβ)2 heterotetramer hemoglobin at higher concentrations, ~40 μM. 
Alpha-cp beta: 
Black: rHb 0.0(PDB 2dn1) 
Red: wt alpha domain of α-cpβ 
Blue: cp beta domain of αcp𝛽 
 
Alpha globin amino acid sequence: 
|M–LSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHG 
|MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHG 
 KKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTP 
 KKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTP 
 AVHASLDKFLASVSTVLTSKYR| 
 AVHASLDKFLASVSTVLTSKYR| 
 
CP beta globin amino acid sequence: 
|MGEFTPPVQAAYQKVVAGVANALAHKYHGSGGQGGGVHLTPEEKSAVTALWGKVNVDEV 
–––EFTPPVQAAYQKVVAGVANALAHKYH| |MVHLTPEEKSAVTALWGKVNVDEV 
GGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKG 
GGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKG 
TFATLSELHCDKLHVDPENFRLLGNVLVCVLAHHFGK| 
TFATLSELHCDKLHVDPENFRLLGNVLVCVLAHHFGK  
 
Figure 13. Comparison of the sequences of wtHb and α-cpβ. In black: rHb 0.0 (PDB 2dn1), in red: wt alpha 
domain of α-cpβ, and in blue: cp beta domain of α-cpβ Hb. 
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Beyond relocation of the β-globin termini through circular permutation, two additional steps 
are required to produce a scHb: intradimer covalent linkage of the α1- & β1-globins and 
interdimer covalent linkage of the α1- & α2-globins as shown in Figure 14. Figure 15 shows 
the plan for adding covalent linkages between specific helices in the target sc-Hb, which will 
be single-chain α-cpβ (sc-α-cpβ). All the proteins shown in Figure 15 have been successfully 
expressed and characterized. 
 
 
Figure 14. Scheme for the development of a single-chain hemoglobin. Red circles are α-
globins, the blue circles are β-globins, the dashes represent polypeptide termini for each 
globin, and connected lines represent covalently bonded termini. 
 
 
 
Figure 15. Proposed steps to introduce the covalent linkages necessary for fusion of the four 
globin subunits into a single-chain hemoglobin. Red circles are α-globins, the blue circles are 
β-globins, the dashes represent polypeptide termini for each globin, and connected lines 
represent covalently bonded termini. 
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Successful expression of α-cpβ enabled analysis of the effects of circular permutation on 
ligand binding affinity and protein structure. The mutant was characterized with high 
performance size exclusion chromatography (HPSEC), electrospray ionization mass 
spectrometry (ESI-MS), laser flash photolysis, and nuclear magnetic resonance (NMR) [12]. 
Characterization of α-cpβ by laser flash photolysis ligand binding assays revealed a 
significant increase in oxygen binding affinity when compared to that of wtHb [11]. This 
shift, associated with circular permutation, limits the oxygen transport capabilities of α-cpβ 
Hb. Efficient O2 delivery to peripheral tissues is dependent upon the release of O2 in low 
oxygen environments, e.g. peripheral tissues, which would be hindered by a shift to higher 
oxygen binding affinity. The shift in oxygen binding affinity is illustrated in Figure 16, a plot 
of log of partial pressure of O2 (log PO
2
) versus fractional saturation of either wild-type Hb 
(HbA) or α-cpβ Hb. For large values of log PO
2
 on the right side of the plot, the hemoglobins 
are predominantly in the oxygen bound (oxy- or R-) state. As O2 partial pressure decreases, 
Hb releases bound oxygen to the surrounding solution; thus, the Hb molecules switch to the 
deoxygenated (deoxy- or T-) state. The midpoint of the transition between oxy- and deoxy-
states indicates the oxygen binding affinity of the protein. In the case of α-cpβ Hb, the 
transition is shifted to the left such that it behaves as if stuck in a state similar to 
hemoglobin’s high affinity R-state [11]. α-cpβ, due to its reduced oxygen binding 
cooperativity, has a similar oxygen binding affinity profile to that of myoglobin (a very high 
affinity oxygen transport protein) as illustrated in Figure 17. 
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Figure 16. Plot of the log of the partial pressure of oxygen of HbA and α-cpβ versus 
fractional saturation with oxygen [11].  
 
 
 
Figure 17. Oxygen binding affinity profiles for myoglobin and hemoglobin. ΔYO2 represents 
the fraction of bound O2 delivered to peripheral tissues as Hb transits from the lungs to the 
capillaries.  
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High performance size exclusion chromatography (HPSEC) was employed to identify the 
extent to which the stability of the T-state had been perturbed. As shown in Figure 18, in the 
oxygenated form (in 50 mM PBS pH 7) the protein exists primarily as a ~30 kDa complex 
and in the deoxygenated form (in 50 mM PBS pH 7 + 5 mM dithionite [binds molecular 
oxygen]) it exists primarily as a ~60 kDa complex by comparing relative elution times to a 
molecular weight standard curve [11]. These data support the hypothesis that circular 
permutation of the β-globin has decreased the stability of the T-state tetrameric hemoglobin 
structure, but does not prevent association of heterodimers when conditions favor the T-state.  
 
 
Figure 18. HPSEC data showing the relative proportion of hemoglobin species for α-cpβ , 
with tetramer (α2β2) @ 20.5 min, and dimer (α1β1) @ 23.2 min [11]. 
 
 
The function of α-cpβ Hb is adversely affected by circular permutation of the β-globin. 
Inspection of the structure of wtHb suggests an explanation for the apparent preference of α-
cpβ for the high affinity conformation. The insertion of the new linker in the cpβ sequence, 
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results in the loss of a salt bridge interaction, which is critical for stabilization of the T state 
[6]. Figure 19 is a simplified schematic of hemoglobin’s subunit domains superimposed with 
hydrogen bonding information obtained from X-ray crystallographic studies. The salt bridge 
between the ε-amino group of α1 K40 and the carboxyl group of β2 H146, the C-terminal 
residue of β-globin, must be absent in α-cpβ because the carboxylate of β2 H146 is an amide 
in the cpβ linker. Without this stabilizing interaction across the 1β2 interface, these α-cpβ 
heterodimers dissociate more readily. This was confirmed by sedimentation equilibrium (SE) 
studies which show a 5-6 kcal/mol (20-24 kJ/mol) loss or ~ 4 orders of magnitude decrease 
in tetramer stability across the α1-β2 interface (Table 1) [13].  
 
 
Table 1. Sedimentation equilibrium (SE) study results for wtHb (rHb0.0) and α-cpβ where Kd is the 
sedimentation equilibrium [13]. 
 
Dissociated heterodimers are known to adopt the R-conformation (and lose cooperativity) 
[11]. Thus the stability of the T-state, which is dependent on a tetramer structure, is reduced 
for α-cpβ Hb. This perturbation of the R to T equilibrium results in an alteration of the 
oxygen binding affinity such that α-cpβ Hb is a functional mimic of myoglobin (see Figure 
17). Thus, increasing favorable interactions between heterodimers across the 1β2 interface is 
key to recovering the desired oxygen binding cooperativity in a permuted Hb. 
 
SE SV
Sample Kd Kd
rHb0.0 0.4-1.3 nM
alpha-cp-beta 4.3-9.8 mM 4.5 mM
dialpha-cp-beta N/A
sc- alpha-cp-beta 14.1-15.4 mM 13.3-13.7 mM
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Figure 19. Illustration of important interactions that stabilize the T-state of hemoglobin [5 
(used without permission)]. α-globins are in red, β-globins are in blue , and the circles show 
X-ray crystallographic detail at the α1β2-interface. 
 
It is not clear from published preclinical data (reviewed in [13] what the P50 and Hill 
coefficient (a measure of cooperativity) for an HBOC must be to enable effective oxygen 
transport in vivo. In the absence of definitive clinical data, our initial targets for O2 binding 
affinity and cooperativity are those of whole blood. In contrast to the “directed evolution” of 
protein function, a more targeted approach to protein engineering is guided by structural 
information. Thus, we require an atomic-resolution structure of α-cpβ to identify mutations 
that might improve permuted Hb function. In the absence of such structural information for 
α-cpβ, published X-ray crystal structures were used to suggest stabilizing mutations. Two 
potential avenues of tetramer stabilization emerged, covalent linkage of the α-cpβ dimers 
through addition of a single glycine residue between the α1- and α2-globins (i.e., the 
Somatogen strategy shown as Step 1 of Figure 6), and introduction of the well-characterized 
stabilizing mutation βK82D. The first approach produced a permuted Hb composed of a 
covalently liked diα-globin that associated with two cpβ-globins (diα-cpβ); the second 
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approach resulted in a tetrameric hemoglobin containing two α-globins and two cpβ-globins 
with the K82D mutation (α-cpβ K82D), both are illustrated in Figure 20.  
 
Figure 20. Protein engineering schemes to increase the stability of T-state hemoglobin. Red 
circles are α-globins, the blue circles are β-globins, the dashes represent polypeptide termini 
for each globin, golden stars represent the K82D mutation, and connecting lines represent 
covalently bonded termini. 
 
NMR was employed to determine the effects of these mutations on the Hb structure. NMR 
spectra collected on various Hb isoforms (O2-bound, CO-bound, and deoxy-Hb) provided 
evidence for α1β1 and α1β2 interactions similar to those in wild-type Hb [12]. It must be noted 
that the protein concentration in the NMR samples is ~ 1 mM, which is significantly higher 
than would be expected in circulation following transfusion of an HBOC. These high 
concentration conditions favor association of the relevant subunits to give the 64 kDa 
complex.  
 
The proton NMR spectra shown in Figure 21 illustrate the peaks that correspond to 
interactions within (indicated by “R”) and between (“T”) heterodimers in the deoxygenated 
state of Hb [12]. The peaks labeled with a blue ‘T’ are indicative of interactions present only 
in the T-state tetramer. These 1-D 1H NMR data suggest that association of the subunits in α-
cpβ is altered and/or reduced compared to that in wt Hb, and that in diα-cpβ the T-state 
interactions are recovered (compare left and right panels of Figure 21).  
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Figure 21. Proton NMR spectra of deoxy (T-state) form hemoglobins. ‘R’ in red indicates 
interactions within a heterodimer and ‘T’ in blue indicates interactions between heterodimers 
[15]. 
 
 
 
Figure 22. Proton NMR spectra of carbonmonoxy (R-state) form hemoglobins. The vertical 
line labeled with “α1β2 marker” indicates a peak in rHb0.0 that is indicative of an interaction 
between groups on opposite heterodimers across the tetramer interface [15]. 
 
In addition to these structural data, functional data were collected for these mutants. 
Equilibrium oxygen binding curves (Figure 23) show the effects that our mutations had on 
recovering native-like oxygen binding affinity and cooperativity. It appears that, at best, 
modest gains were made with α-cpβ K82D Hb to return to a wtHb oxygen binding affinity 
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profile, but these data are preliminary. The binding curves for α-cpβ and diα-cpβ are nearly 
superimposable; thus, the functional data do not support the conclusions of the NMR studies 
shown above. This apparent discrepancy is likely due to the different protein concentrations 
used for the binding studies (10 μM) vs. the NMR experiments (300 μM). 
 
 
Figure 23. Plot of the log of the partial pressure of oxygen of HbA and mutant hemoglobins 
versus partial saturation with oxygen. [16]. 
 
Greater structural detail of the interactions between α-cpβ dimers is needed to better 
understand how circular permutation affects permuted Hb structure, stability, and function. 
The present work was undertaken to determine an atomic-level structure of α-cpβ, and 
thereby inform a rational protein engineering strategy aimed at recovering the stability of the 
T-state.  
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The permuted Hb proteins are of a size that would render structure determination by solution 
methods, e.g. NMR, highly challenging. Thus, we chose to approach elucidation of the 3D 
structure through the method of X-ray crystallography. X-ray crystallography is the process 
by which crystals of a given molecule may be analyzed with monochromatic, high flux X-
rays to determine the electron density within the repeating unit of that crystal, as illustrated in 
Figure 24. The electron density maps produced from this technique can then be populated 
with a theoretical model of the molecule in the crystal. The resulting model is then modified 
to best fit the experimental data.  
 
 
Figure 24. Structure determination by the X-ray crystallography process. Arrows indicate 
progression of steps in the process.  
 
The first and arguably most arduous step in this process was the production of protein 
crystals with properties enabling the collection of high resolution diffraction data. The 
hanging drop method of protein crystallization was employed to screen crystallization 
conditions and to produce diffracting crystals. Driven by vapor diffusion, the hanging drop 
method facilitates the growth of crystals in a sealed system. The concentration of precipitants 
in the protein solution gradually increases via transfer of water vapor from hanging drop to 
mother liquor to the point that the protein precipitates, hopefully at a controlled rate such that 
crystals are formed [17]. A high degree of structural order (crystallinity) within the crystal, 
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monocrystalline composition, and sufficient size are characteristics that indicate a crystal 
should produce higher resolution diffraction patterns. The variability in the quality of the 
crystals combined with the difficulty of identifying conditions that promote growth of 
monocrystals, make X-ray crystallography a challenging and artful task. 
 
Ambiguity in the interpretation of the diffraction data is engendered by the loss of phasing 
information. Phase information can be recovered partially through three common methods, 
multiple isomorphous replacement (employing integration of heavy atoms within the crystal 
to give phase guides), molecular replacement (utilizing a known homologous structure to 
assign phase computationally), and multi-wavelength anomalous dispersion (coherent X-ray 
light of different wavelengths are diffracted off the crystal at a synchrotron facility. As many 
high resolution hemoglobin structures exist and are readily accessible, molecular replacement 
was our chosen method to solve this phasing problem.  
 
Once a diffracting crystal has been obtained, diffraction data collected, and the phase 
problem resolved, refinement of the molecular model for optimal fitting of the electron 
density begins. Refinement is an iterative process. As the model more closely fits the density, 
the resolution of the density maps improves, which in turn enhances the quality of the data 
available to fit the map. This iterative process is essential and is a function of the 
mathematical operations employed to ascertain the electron density maps from the pattern of 
X-rays diffracted by the crystal.  
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Materials and Methods: 
 
Expression of Hemoglobins 
Proteins were expressed in E. coli using plasmids developed previously [11]. One liter flasks 
of terrific broth (TB: 12 g tryptone, 24 g yeast extract, 4 ml glycerol, 2.31 g KH2PO4, and 
12.54g K2HPO4, fill to 1000ml with dH20) were inoculated with 10 mL of E. coil overnight 
culture (10 mL of LB in a 50mL flask shaken overnight at 37 °C), and incubated at 37 °C 
with shaking until an optical density at 600 nm of 0.7-0.9 was attained. The flasks were then 
cooled to 30°C and shaken until they reach an OD600 of 1.5 to 1.7, at which point IPTG was 
added to a final concentration of 1mM to induce protein expression. Shortly after, 1.5 g of 
hemin in 20mM sodium hydroxide was added to each flask, an identical aliquot of hemin was 
added 2 hours and 4 hours following induction. 6 hours after induction, the flasks were 
removed from the orbital shaker and the cells were harvested by centrifugation at 5,000 × g 
for 10 minutes. The supernant was discarded and the pelleted cells were collected and flash 
frozen in liquid nitrogen. Frozen cells were stored at -80 °C until they were thawed for 
protein purification.  
 
In the optimized process for production of the α-cpβ protein the E. coli were grown in TB to 
an OD600 of 0.7-0.9 at 37 °C, at which point the temperature was reduced to 30°C for α-cpβ 
or 32°C for diαcpβ and allowed to reach an OD600 of 1.5-1.7. At this point, protein 
expression was induced with 1.00 mM isopropyl β-thiogalactopyranoside (IPTG). Cells 
expressed α-cpβ for 5 hours for α-cpβ or 7 hours for diαcpβ at 30 °C before being harvested 
by centrifugation and flash freezing in liquid nitrogen.  
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Purification 
Following the protein expression period, bacterial growth media was centrifuged at 5000 x g 
for 10 minutes to pellet the cells. Pelleted cells were harvested, flash frozen in liquid 
nitrogen, and resuspended in lysis buffer (50mM Tris-HCl pH 8.5, 17 mM NaCl). Cell 
suspensions were then lysed via sonication with a Branson Sonifer 450, fitted with a 1.8 cm 
diameter horn, for 90 seconds with a duty cycle of 50% and power output set to 6. The crude 
lysate (Figure 25) was then separated into soluble and insoluble fractions via centrifugation 
at 21,000 x g for 20 minutes, soluble fraction was collected and the pH was adjusted to 
between 8.0 and 8.5 to improve protein binding to the IMAC resin. Permuted and wild-type 
hemoglobins bind to zinc ions present on the charged IMAC column, 4 mM zinc acetate was 
added to the supernant to facilitate precipitation of contaminating cellular components that 
also possess Zn2+ binding affinity. Precipitated proteins were removed from the supernant via 
centrifugation at 40,000 x g for 20 minutes and filtration through a 0.45 µm pore size 
cellulose acetate membrane (Millipore).Purification procedures were adapted from published 
procedures [11] with the exclusion of the 250mM NaCl step in the IMAC phase of 
purification. In addition, the proteins were not frozen between each purification step, rather, 
they were kept at 4°C until purification was finished and then used immediately or flash 
frozen in liquid nitrogen for long-term storage.  
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 Immobilized Metal Ion Affinity Chromatography (IMAC) 
The IMAC column was hand-packed with ~ 10mL of Amersham-Pharmacia Biotech Chelation 
Sepharose Fast Flow Resin. Flow was maintained at 6 mL/min by a Bio-Rad EP-1 Econo 
Pump. Preparation and operation of the column is described in Table 2. 
 
 Table 2. IMAC wash steps. 1 CV = 10 mL. 
 
 Buffer Column volume (CV) Flow rate 
Column preparation 
1.  0.2 M NaCl 2  4 mL/min 
2.  20 mM Zn(OAc)2 2 4 mL/min 
3.  0.2 M NaCl 2  4 mL/min 
Protein purification 
4.  Lysate - 4 mL/min 
5.  20 mM Tris-HCl, 0.5 M NaCl, pH 8.5 8  4 mL/min 
6.  20 mM Tris-HCl, pH 8.5 6  4 mL/min 
Protein elution 
7.  20 mM Tris-HCl, 15 mM EDTA, pH 8.5 - 2 mL/min 
Column cleaning 
8.  50 mM EDTA 2  4 mL/min 
9.  0.2 M NaCl 2 4 mL/min 
10.  0.2 M NaOH 2  4 mL/min 
 
Eluent fractions containing the mutant Hbs were collected and concentrated with Millipore 
Amicon Ultra Centrifugal Filter Devices (Amicon Ultra-15 or Amicon Ultra-4, 10 kDa filter) 
and filtered through Corning Spin-X Centrifuge Tube Filters (0.22 µm cellulose acetate). The 
Beer-Lambert law was employed to calculate preliminary protein expression yields from the 
heme Soret absorbance peak (410-418 nm) with εheme of 125,000 M-1 cm-1. 
 
Mono Q ion exchange (IEC) 
Fractions pooled following IMAC were buffer exchanged into 20 mM Tris-HCl pH 8.0 (buffer 
A) with a Millipore Amicon Ultra Centrifugal Filter. Samples were then purified on an 
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Amersham Biosciences MonoQ 5/50 GL column connected to either a Waters 650E Advanced 
Protein Purification System and a Waters 486 Tunable Absorbance Detector or a GE Health 
Sciences Äktapurifer 900 system. The proteins were immobilized on the resin and subsequent 
washes with increasing salt concentration promoted elution of contaminants as described in 
Table 3. Fractions containing Hb were collected and concentrated as mentioned above.  
 
 Table 3. IEC (Mono Q) purification protocol 
 
 Buffer Column Volume (CV)  Flow rate 
Column preparation 
1.  Buffer A 5  2 mL/min 
2.  Buffer B (20 mM Tris-HCl, 1 M NaCl, pH 8.0) 5  2 mL/min 
3.  Buffer A 5  2 mL/min 
Protein loading 
4.  Load IMAC pool - - 
5.  Buffer A 2  2 mL/min 
Protein elution (linear gradient program) Time course 
6.  100% Buffer A 0:00 2 mL/min 
80% Buffer A, 20% buffer B 3:00 2 mL/min 
30% Buffer A, 70% Buffer B 28:00 2 mL/min 
100% Buffer B 29:00 2 mL/min 
Column cleaning Column Volume 
7.  Buffer B 2  2 mL/min 
8.  Buffer C (2 M NaCl) 2 2 mL/min 
9.  1 M NaOH 4  2 mL/min 
 
11. 
ddH2O 
20% v/v EtOH (storage buffer) 
2  
2  
2 mL/min 
2 mL/min  
 
Size Exclusion Chromatography (SEC) 
Following purification by MonoQ, samples were further purified on an Amersham Biosciences 
Superdex 75 HR 10/300 GL size exclusion column connected to a Waters 650E Advanced 
Protein Purification System and a Waters 486 Tunable Absorbance Detector or the Äktapurifer 
900 system. Purification by SEC was accomplished by the process described in Table 4. SEC-
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purified samples were concentrated and final post purification yields were calculated from 
Soret band absorbance measurements as described above. 
 
 Table 4. SEC purification protocol 
 Buffer Column Volume Flow rate 
Column preparation 
1.  ddH2O 2 CV 1 mL/min 
2.  20 mM ammonium acetate (NH4OAc), pH 7.0 1 CV 1 mL/min 
Protein elution  
3.  20 mM NH4OAc, pH 7.0 - 1 mL/min 
Column cleaning 
4.  20 mM NH4OAc, pH 7.0 1-2 CV 1 mL/min 
5.  ddH2O 1-2 CV 1 mL/min 
6.  0.5 M NaOH 1-2 CV 1 mL/min 
7.  ddH2O 1-2 CV 1 mL/min 
8.  20% v/v EtOH 1-2 CV 1 mL/min 
 
 
 
Protein Characterization 
 
Purified proteins were analyzed for purity and molecular weight by SDS-PAGE. Electrospray 
Ionization Mass Spectroscopy was performed at the WWU Scientific Instrument Center 
using an Applied Biosystems API 2000 Triple Quadrupole. Samples were prepared in 50% 
(v/v) acetonitrile, with 25mM ammonium acetate buffer pH 7.0, and 0.1% formic acid. 
  
Preparation of cyanomet hemoglobin isoform 
Conversion of oxy-Hb to the cyanomet isoform, prior to analysis by ultracentrifugation, was 
achieved using Drabkin’s reagent as described previously [26] with the single modification 
that a 5-fold excess of potassium ferricyanide to heme concentration of protein was used.  
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Preparation of protein for crystallization 
Protein stocks of α-cpβ hemoglobin were purified to greater than 95% purity at a 
concentration of 10 mg/mL in 100 mM ammonium acetate, pH = 7, for crystallography. The 
hanging drop method of protein crystallization was applied in 24-well crystallography trays 
as follows: the rims of the wells in the crystallography plate were coated in white petrolatum 
to prevent dehydration of the experimental solution in the well, a 400 uL aliquot of 
precipitant solution (the mother liquor) was added to each well, 1 uL of concentrated protein 
solution and 1 uL of mother liquor were pipetted onto a siliconized glass cover slip, and the 
glass slip was inverted and sealed to the greased crystallization well. The hanging drops were 
examined for crystal formation at regular intervals with a compound microscope and crystal 
formation was recorded with a digital camera. 
 
Shotgun approach 
The shotgun approach was used to screen for crystal promoting conditions for mutant 
hemoglobins. Standard screening solutions were purchased from Emerald BioStructures and 
Hampton Research. The following Hampton Research solutions were evaluated with α-cpβ: 
Index, Crystal Screen, PEG/Ion, PEGRx, and Crystal Screen Cryo. Mixtures of polyethylene 
glycol 2250 (PEG2250) at concentrations of 20-30% w/v, polyethylene glycol monomethyl 
ether 1250 (PEGMME1250) at concentrations of 20-30% w/v, 0.2 M ammonium acetate, 0.2 
M sodium chloride, 0.1 M Bis-Tris buffer at pH 5.8-7.0, and 0.1 M Tris-HCl at pH 8.5 to 9.0 
produced crystals that were suitable for X-ray diffraction studies.  
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Identification of ‘hits’ 
Any solutions from the initial shotgun screening that produced crystals were considered to be 
leads, or ‘hits’, that were used as starting conditions to determine optimal condition grids that 
would promote better crystal morphologies.  
 
‘Gridding’ around hits 
Precipitant solution composition from the initial hits obtained from the shotgun approach was 
varied to optimize crystal morphology and size. Optimum crystal morphology was identified 
by crystals that appeared clear and regularly geometric. PEG 3350 concentrations and pH 
were varied until a narrow range of conditions were identified as optimum for these two 
variables. Variation from standard conditions of 0.2 M salt and 2 uL drop volume failed to 
improve crystal morphology and quality. 
 
Catalogue of crystals 
Many distinct crystal morphologies were observed during the optimization process. Sheet, 
spike, cluster, and many other geometries were observed; each geometry exhibited a 
continuum of crystalline order from opaque multi-crystals to transparent single crystals, see 
Appendix A. Well conditions resulting in crystals of desirable morphologies (regular 
geometric in shape, single crystal, large, and optically transparent) were identified. Gradient 
trays were formulated in a fine grid around these optimal well conditions in an attempt to 
further improve resultant crystal morphologies. After fine optimization, whole trays would be 
plated with identical optimized well conditions to produce many optimal crystals. 
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Selection & harvesting of crystals for X-ray crystallography 
 Optically transparent, isolated crystals larger than 0.2 mm, were captured with a 
crystallography loop (Hampton Research catalogue #: HR4-957) . Preserved crystals were 
quickly transferred to a cryoprotectant solution identical to the mother liquor with the 
addition of 10-30% dimethylsulfoxide (DMSO), glycerol or Polyethylene glycol 400 
(PEG400) and examined for stability in that solution. A trial and error approach was needed 
to identify which solution would protect the crystal without damaging its integrity. 20% 
glycerol was determined to be optimal for most crystals and so was used almost exclusively. 
Once successfully cryoprotected, the crystal was looped again and flash frozen by 
submerging in liquid nitrogen. Great care was taken to avoid contact with air from this point 
on as ice crystals will form rapidly on the frozen crystal; these ice crystals will interfere with 
collection of diffraction data, but can be removed by quickly thawing and refreezing the 
crystal. The crystals were stored in magnetically sealed tubes under liquid nitrogen until they 
were to be evaluated by X-ray diffraction.  
 
X-ray crystallography 
Eleven diffraction data sets were evaluated on the α-cpβ hemoglobin crystals with an AFC11 
SATURN 944 Right system and Cu Kappa radiation at 1.54Å from a Rigaku rotating anode 
generator. Data collection for these crystals was performed at the Fred Hutchison Cancer 
Research Institute, Seattle, WA. Diffraction data was collected and processed by Dr. P. Clint 
Spiegel with HKL2000 and D*trek for the α-cpβ eight crystals evaluated. Crystals were 
removed from storage in LN2, transferred to the mounting arm via a magnetic 
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crystallography loop and kept at LN2 vapor temperature by a cryostream. If ice rings were 
detected in the diffraction pattern, crystals were removed from the cryostream  
 
Evaluation of data set 11 (hb8) and molecular replacement 
This portion of the work was performed by Dr. P. Clint Spiegel of Western Washington 
University, Department of Chemistry. The search model used was a high resolution oxy-
hemoglobin structure from the PDB, PDB code 2dn1.  
 
Calculation of electron density maps 
Electron density maps were calculated with the Phenix.maps subroutine from the PHENIX 
macromolecular structure refinement suite [23]. Each refinement of the electron density 
produced two calculated maps, which guided model refinement. These calculated maps 
represented, respectively, the density of the model plus those features that had not been 
modeled yet (composite map) and density features that were not directly attributed to the 
model (difference map). The first of these maps was calculated by subtracting the absolute 
value of the Fcalculated, or Fc, map from two times the absolute value of the Fobserved, or Fo, map 
(2fo-fc) and the second is calculated by subtracting the absolute value of the Fc, map from the 
Fo map (fo-fc).  
 
Automated structure refinement 
The Phenix.refine subroutine of the Phenix software package was employed for automated 
refinement of the model. Alternating rounds of optimization weighted for biophysical 
parameters (bond angles and lengths) and for electron density fit were applied to the structure 
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to achieve a concurrent lowering of the Rwork and Rfree values. This alternation of fitting 
parameters enabled automated optimization of biophysical constraints and density fit while 
avoiding undesirable perturbations to the structure by the computer aided structure 
refinement package. These perturbations often remodeled difficult to define portions of the 
structure or placed residues into impossible orientations.  
 
Manual structure refinement 
WinCoot [24] was employed to manually fit many of the side-chains, terminal residues, 
ligands and waters. The full suite of tools and analysis packages available on the program 
was applied to develop the final model. 
 
Validation of structure refinement 
The Phenix.validate subroutine of the Phenix software package was employed to validate the 
structure by comparison with other models of similar resolution from the PDB.  
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Results and discussion: 
 
To produce crystals of high quality, relatively large amounts of protein (>10 mg) at ~95% 
purity must be obtained. This requirement was initially challenging due to the low expression 
levels of the mutant proteins (approximately 1.2 mg of α-cpβ per 1 liter of growth media 
following the first purification step). Greater than 50% of this 1.2 mg was lost in the final 
purification steps, requiring upwards of 18-34 liters of bacterial culture to produce the final 
10 mg of purified α-cpβ protein. Optimization of permutein expression reduced the media 
requirement to approximately 4 liters, this enabled production of material in quantities 
sufficient for crystallography.  
 
Growth optimization 
As shown in Table 5, yields of 1.2 mg α-cpβ per liter of culture, following immobilized metal 
ion affinity chromatography (IMAC) purification, were typical at the outset of this work. 
Other permutants expressed at even lower levels (0.1 mg diα-cpβ/L and 0.3 mg sc-α-cpβ/L), 
likely stemming from greatly reduced apoprotein stability [18]. These levels of protein 
expression are insufficient to support X-ray crystallography and NMR studies- particularly if 
isotopic labeling is required. Thus, protein yield enhancement was pursued through two 
avenues, optimization of the protein expression protocol conditions and insertion of a heme-
uptake gene (hug) cassette [19].  
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 Table 5. Growth optimization data for hemoglobin mutants. Data collected from many past 
and present research group members.  
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Protein expression protocol optimization was accomplished through modulation of: medium 
formulation, target OD600 for induction, concentration of isopropyl β-D-1-
thiogalactopyranoside (IPTG) added at induction, concentration and number of hemin 
additions post-induction, free glucose concentration, the temperature during protein 
expression, and length of induction. An expression yield enhancement of 4-50 fold was 
observed for the suite of proteins listed in Table 5 (1.2 to 5.8 mg/L for α-cpβ, 0.1 to 5.4 mg/L 
for diα-cpβ, and 0.3 to 2.1 mg/L for sc-α-cpβ). Use of a richer medium with more available 
nutrients (Terrific broth [TB] vs. LB), a higher concentration of IPTG at induction, and an 
increased concentration of added hemin, collectively resulted in a 3-4 fold yield enhancement 
of α-cpβ post-IMAC purification step. Optimization of target OD600 for induction, the 
temperature during protein expression, and length of protein expression period increased 
protein yields again by approximately 60% for αcpβ. 
 
Multiple variables in the expression protocol for α-cpβ were simultaneously modified to 
improve protein yields. Thus, the effect of the hug cassette on protein yield enhancement was 
difficult to isolate. However, improved expression yields of α-cpβ and diαcpβ were generally 
observed when the hug cassette was present in the Hb expression vector. Yield data obtained 
from later experiments with other variants of α-cpβ (which contain stabilizing point 
mutations [20]) failed to correlate the observed enhancement of permuted Hb expression 
levels with the coexpression of the hug cassette (S. Jones, J. Sigurjonsson, unpublished data). 
In the case of diαcpβ, significant yield enhancement was not observed until other variables 
were also altered, namely temperature of expression, target OD600 for induction, and length 
of induction. Further testing to determine the need for the hug cassette was not undertaken as 
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our major goals were structure determination, and we had improved expression yields 
sufficiently to pursue those goals.  
 
Yield enhancements observed for diα-cpβ suggest that target OD600 for induction and length 
of induction are among the most critical parameters to optimize. Protein yield data obtained 
from optimization of sc-α-cpβ expression (Figures 14 and 15; Table 5) also showed that 
significant enhancement in protein yields was not observed until the OD at induction and 
length of induction were increased.  
 
Purification Results 
Proteins were purified from clarified lysate by Immobilized Metal Ion Affinity 
Chromatography (IMAC), Ion Exchange Chromatography (IEC), and Size Exclusion 
Chromatography (SEC) [see Materials and Methods]. 
 
Protein yields 
The rigorous purification procedure required to attain greater than 95% purity (Figure 25) 
resulted in low protein recoveries. Post IMAC yields, detailed in Table 5, were reduced by 
the MonoQ and SEC steps by ~70%. Typical protein recoveries from a 6L α-cpβ expression 
are as follows: 20.1 mg of protein following IMAC, 5.8 mg from the combination of the 
MonoQ and SEC purification steps (29%). Such losses between the first and final 
purification step further emphasized the need for optimization of protein expression 
conditions.  
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Protein purity was determined through sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and electrospray mass ionization mass spectrometry (ESI-MS). 
Densitometry of protein gels was performed using the ImageJ software [21]. An example of 
high purity α-cpβ (98%) and α-cpβ-hug (96%) characterized by this technique is shown in 
Figure 25. ESI-MS characterization of α-cpβ and α-cpβ-hug is shown in Figures 26 and 27. 
Molecular weights (MW) were calculated from ESI-MS m/z ratios with Equations 1 and 2 
(mH = 1.00794) and are compared to their expected MWs in Table 6.  
 
 
Figure 25. SDS-PAGE of α-cpβ proteins. Lane 1 is a protein ladder, standard molecular weights of select bands 
are indicated to the left. Lane 2 and 3 are α-cpβ and α-cpβ-hug samples at high purity (98.0 and 96.0 %). Lane 5 
is a crude lysate of α-cpβ prior to purification efforts.  
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Figure 26. ESI-MS of α-cpβ at high purity (98.0%). 
 
 
Figure 27. ESI-MS of α-cpβ-hug at high purity (96.0%). 
 
 
 (Equation 1) 
 
 
 (Equation 2) 
 
 
 Table 6. Expected and observed MWs for α-cpβ calculated from ESI-MS m/z ratios.  
 
 Expected MW α-cpβ Observed MW α-cpβ
15,159.42 (-globin) 15,158.75 (-globin)
16,556.94 (cpb-globin) 16,571.39 (cpb-globin)
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Unexpected higher MW contaminants 
As shown in Figure 28, SDS-PAGE gels of α-cpβ that had been purified with freeze/thaw 
cycles between each purification step exhibited four bands of varying intensity at expected 
MWs for α-cpβ (15 and 16.5 kDa) and at unexpected higher MWs (30 and 33 kDa. Bands at 
30 and 33 kDa suggest the presence of cross-linked proteins that are twice the mass of the α- 
(15 kDa) and cpβ- (16.5 kDa) globins, respectively. The intensity of these higher MW bands 
was shown to increase as a result of protein conversion to the cyano-met isoform and after 
repeated flash freeze/thaw cycles. Thus, the purification process was altered to exclude the 
flash freezing between purification steps. Samples were instead refrigerated at 4°C between 
chromatography steps. This modification reduced the presence of these bands to below 
detection levels (Figure 29).  
 
 
Figure 28. SDS-PAGE of cyano-met isoform hemoglobins. Lanes were overloaded to better assay impurity 
levels. ‘Monomer weight’ indicates approximate MW of monomeric globins and ‘Dimer weight’ indicates 
approximate MW of dimeric globins. wtHb should have 100% monomeric globins, α-cpβ should have 100% 
monomeric globins, and diα-cpβ should have 50% monomeric and 50% dimeric globins. 
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Figure 29. SDS-PAGE gel of α-cpβ and diα-cpβ at normal loading (lanes 2 and 3 respectively) and at over 
loaded concentrations to illustrate purity (lane 4) following elimination of freeze/thaw cycles. 
 
 
Sparse matrices 
Crystallization trials were performed, as describe in Materials and Methods, to produce 
diffraction quality crystals of α-cpβ and di α-cpβ, an example image can be seen in Figure 
30. Roughly 1500 individual crystallization experiments were performed in ~70 individual 
24-well crystallization plates. Before attempting to crystalize α-cpβ, data published for 
hemoglobin structures deposited in the Protein Data Bank (PDB) were examined for 
conditions that promote production of diffraction quality crystals (Table 7). Neutral pH and 
20° C appeared to be common variables, which proved to promote production of diffraction 
quality crystals in α-cpβ and diα-cpβ as well. Sparse matrix gradients resulted in many wells 
containing microcrystals that appeared too small for diffraction studies directly, but indicate 
good conditions to screen around. The α-cpβ was tested against the following sparse matrices 
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(the number of promising hits from each matrix are given in parentheses): Cryo II (1), 
Hamilton Crystal Screen (3), Index (9), and PEG/ION II (1). Many hits resulting from the 
shotgun approach were very small micro crystals of less than 0.01 mm in diameter. Fourteen 
hits were identified for further optimization by forming a gradient of conditions around the 
mother liquor composition for each hit. The Index screen from Hampton Research produced 
the best results, closest to the ideal single crystals of greater than 0.1 mm in diameter free 
from visible defects, for all of the permutants.  
 
 
Figure 30. Image of stacked 24-well crystallization trays with 2µL α-cpβ crystallization trials (red dots). 
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 Table 7. Crystallization conditions reported for hemoglobin structures in the PDB.  
 
 
 
Gradient trays 
Gradient trays (Figure 31) were formulated (see Table 8) around these hits to explore the 
effects of small variations in crystallization conditions on crystal morphology. Trays labeled 
with a number only were stored at ambient room conditions (~25°C), while those with a 
number and the letter ‘x’ were stored at a constant 20°C. These gradient conditions produced 
numerous crystals with a variety of morphologies illustrated in Figures 32 – 39, crystals 
identified by blue arrows had desirable morphologies for X-ray diffraction.  
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 Table 8. Tabulation of gradient crystallization conditions extrapolated from sparse matrix hits for α-cpβ. 
 
 
 
 
Figure 31. General layout of a gradient tray. Concentration of PEG 3,350 (w/w)% varies along the horizontal 
axis and pH varies along the vertical axis to create a grid of finely tuned conditions.  
 
44 
 
 
Figure 32. Tray 11 crystal results (100x light microscope) for α-cpβ. 
 
 
Figure 33. Tray 12 crystal results (100x light microscope) for α-cpβ. 
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Figure 34. Tray 2x crystal results (100x light microscope) for α-cpβ.  
 
 
 
Figure 35. Tray 7x crystal results (100x light microscope) for α-cpβ. 
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Figure 36. Tray 9x crystal results (100x light microscope) for α-cpβ.  
 
 
 
Figure 37. Tray 10x crystal results (100x light microscope) for α-cpβ. Three enlarged examples of 
microcrystals are shown for well 24a.  
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Figure 38. Tray 11x crystal results (100x light microscope) for α-cpβ.  
 
 
 
Figure 39. Tray 12x crystal results (100x light microscope) for α-cpβ 
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Attempted analysis of birefringence by polarized light microscopy 
Polarized light microscopy can be used to evaluate the degree of crystallinity of target 
crystals [22]. The birefringence of crystalline materials can be observed with polarized light 
microscopy as a shift in the color of the crystalline material. Evaluation of crystals via this 
technique and selection of those most strongly birefringent, improves the chances of 
selecting a crystal for X-ray diffraction that will diffract at high resolution [22]. Application 
of polarized light microscopy met with varying degrees of success. The birefringence of the 
polystyrene crystallography trays severely impacted the sensitivity of the technique as the 
birefringence of protein crystals had to be detected over the background birefringence of the 
plastic, as illustrated in Figure 40. Even with this interference, detection of protein crystal 
birefringence was possible and strongly observed in some cases (Figures 41 and 42). Many 
promising protein crystals were identified with this technique; unfortunately the heat 
produced by the microscope resulted in destruction of all crystals analyzed. Though 
application of this technique has many hurdles to overcome, if non-birefringent trays could 
be obtained and if the crystals could be evaluated in a refrigerated area this technique could 
increase efficiency of crystal screening and enable collection of crystals more likely to 
diffract at high resolution [22].  
 
Figure 40. Example of birefringence of the polystyrene trays. 
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Figure 41. Examples of α-cpβ crystals under normal light (top) and polarized light with a cross 
polarized filter (bottom).Brighter sections in the polarized images are caused by higher birefringence 
which indicated greater order of the crystal. 
 
 
 
 
Figure 42. Examples of diα-cpβ crystals under normal light (top) and polarized light with a cross 
polarized filter (bottom). Brighter sections in the polarized images are caused by higher birefringence 
which indicated greater order of the crystal. 
 
Catalogue of crystal morphologies 
Many of the observed crystal morphologies were transient in nature, forming and 
disappearing at distinct time points. In an effort to track these morphologies and the 
conditions that promoted their formation, the crystals were imaged and organized into 
categories with qualifiers. A color coded system was developed to enable quick visual 
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assessment of a tray’s potential to develop diffracting crystals. In addition to facilitating 
review of past results, this system enabled observation of trends in crystal forming ability as 
a function of mother liquor composition and time.  
 
Optimized mother liquor 
The conditions that promoted single crystal formation were similar to those that had 
previously crystallized wild-type hemoglobin and mutants developed by other labs. The ideal 
condition range, identified by the property of producing diffracting crystals of α cpβ, was a of 
pH 6.5 – 8.0 and 22-24% (w/w) PEG 3350. The condition that produced the crystal that was 
ultimately used to collect diffraction data to 2.7 Å was 0.1 M Bis-Tris at pH 6.5 with 24% 
(w/w) PEG 3350. 
 
Selection of crystals to send for X-ray diffraction 
Crystals were selected for qualities that are commonly associated with higher levels of 
diffraction, namely clarity, size, geometric regularity, and stability in cryobuffer solutions. 
Selection for crystals with these properties generally increases the chances of obtaining 
higher resolution diffraction data, but counterintuitive examples abound and a seemingly 
‘perfect’ crystal is not guaranteed to diffract well. The crystals described in Table 9 were 
selected for X-ray analysis based on their likelihood to diffract. Of the 21 crystals sent for X-
ray diffraction at the Fred Hutchison Cancer Research Center, 8 individual crystals were 
analyzed over 11 X-ray diffraction experiments (Table 10). Two crystals diffracted above 4 
Å, five above 3 Å, two at 2.8 Å and one at 2.7 Å. The 2.7 Å data set was selected to calculate 
the electron density maps, and ultimately the structure of α-cpβ. 
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 Table 9. Tray origin of α-cpβ crystals and cane position for X-ray diffraction. “Crystal” is abbreviated ‘xtal’. 
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 Table 10. Crystal diffraction information for α-cpβ crystals. 
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Diffraction Data 
The crystal hb8 diffracted to the highest resolution and yielded space group dimensions 
expected for a molecule the size of a hemoglobin tetramer (64kDa). A high resolution (1.25 
Å) human oxy-hemoglobin structure (PDB ID: 2dn1) was employed to calculate the phasing 
information of the α-cpβ model and to solve the phase problem with the Phenix software 
suite [23]. Diffraction data were collected at lower resolution (Figure 43) and ultimately to 
2.7 Å resolution (Figure 44), which enabled identification of the main chain atoms, the shape 
of side chains, and tightly bound water molecules. This level of resolution provides clear 
evidence of the expected locations of the new linker and termini in the cpβ globin, as well as 
native-like association of the α-cpβ heterodimers within a 64 kDa complex.  
 
 
Figure 43. Diffraction patterns of α-cpβ crystals at lower resolution. Patterns originated from 
crystals indicated in lower left of each diffraction pattern. 
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Figure 44. One diffraction pattern collected for the data set used to calculate electron density 
maps used to refine the α-cpβ model from the highest resolution diffraction data set. 
 
Refinement  
The first step in the process of refining the initial model was to look for areas of mismatch 
between the electron density and of the density predicted by the model. If the density was 
absent for a portion of the model (side chain or residue), it was reoriented to a position 
supported by electron density, or it was deleted for subsequent modeling when the structure 
was more highly refined. If there was density present that was not occupied by the model, it 
was populated with a misplaced residue or water molecule. The molecular modeling 
program, WinCoot, [24] has different levels of user control that enable either direct manual 
manipulation or computer aided optimization of the model best fit to electron density using 
biophysical constraints to minimize intramolecular strain within the model. 
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The goal of refinement is to optimize bond angles, bond lengths, and occupation of electron 
density. This requires compromise between strain minimization (achieved by alteration of the 
covalent bonding parameters) and maximization of electron density occupation. In the initial 
stages of model refinement, significant bias was placed on fitting the model to the electron 
density. After the initial optimization for electron density this bias was removed, and the 
model was adjusted to conform to standard parameters for bond angles and lengths (within an 
acceptable range of variation). 
 
The original model was modified through a process combining manual manipulation of the 
structure and computer aided optimization. The general process was to examine the model 
produced by the Phenix software, with the molecular modeling software WinCoot. WinCoot 
enabled the visualization of the electron density plots produced by Phenix and fitting of the 
preliminary models to this electron density. 
 
Further refinement of the initial model was accomplished by comparing density predicted by 
the model to density supported by the data. The putative quality of intermediate models was 
assessed by determining how accurately the model predicted the observed data. There is a 
bias created by this process because it is possible to over fit the model to the calculated 
electron density maps. To prevent this over fitting of the model to a structure that is not 
correct, a percentage of the original data points are reserved and omitted from 
computationally aided refinement steps. These omitted data points are employed to validate 
the model refinements through a process that discerns if they could be produced by the 
electron density of the refined model. The degree to which these parameters validate the 
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current model are indicated by a score, Rfree, which has a value between 1 and zero, with zero 
being a perfect fit. An Rfree value of less than 0.27 was our target for the refinement. 
 
Refinement of the α-cpβ model was initiated by fitting a model of wild type tetrameric 
hemoglobin (PDB ID: 2dn1), omitting all ligands, to the electron density maps produced by 
the 2.7 Å resolution diffraction data. This was followed by deletion of any residues that were 
not supported by the electron density maps. The residues linking the G- and H- helices of the 
cpβ-globin had very weak density, indicating that they were not well resolved, or absent in 
the crystal structure, and so were deleted. This observation is not surprising given the 
expectation that α-cpβ should have new termini at this location. Following this initial 
truncation of the model, the electron density maps were recalculated and used to adjust the 
secondary structural elements of the model to better fit the electron density. 
 
The initial search model lacked the functionally essential heme group. The correct placement 
of this iron-containing ligand in the α-cpβ structure greatly improved the quality of the 
electron density maps calculated with the model, due to the relatively dense iron atom at the 
core of the heme group. Placement of the heme ligand was strongly supported by the 
observation of electron density, which was isolated in the putative α-cpβ heme binding 
pocket, and had a volume that closely matched the molecular dimensions of heme. Once in 
place, the quality of the electron density maps markedly improved, and density supporting a 
ligand bound to the heme group became apparent. This density was fit with both a single 
oxygen atom to simulate the aquomet, or water bound, form of Fe3+ hemoglobin and 
dioxygen to simulate the Fe2+- O2 bound form. The dioxygen better occupied the density 
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provided by the diffraction data and yielded a greater reduction in Rfree. Thus, we concluded 
that our structure was of an oxy (Fe2+) hemoglobin, which was expected as the α-cpβ protein 
was crystallized under ambient atmospheric conditions. 
 
The process of fitting additional resides to this intermediate model began by constructing a 
generic peptide backbone in the areas of unfilled density using alanine or glycine residues. 
After the backbone had been correctly modeled with alanine and glycine residues, the density 
maps were recalculated and the correct amino acid was exchanged for the substitute residue. 
This process was much more effective, on average, than attempting to insert the intended 
amino acid directly. The electron density of the side chain atoms was relatively low 
compared to those of the peptide backbone, especially for residues with flexible side chains 
(lysine, aspartic acid, etc.). The majority of the amino acids predicted by the α-cpβ gene were 
supported in their correct order through the application of this process, with the exception of 
C-terminal residues on the α-globin and the cpβ-linker residues on the cpβ-globin. It is likely 
that the density of these residues was difficult to extract from the data due to the relatively 
high conformational flexibility expected for residues in these positions. 
 
After 48 rounds of manual and 172 rounds of automated structure and map refinement, the 
peptide backbone and side chains for these residues were placed with good to poor fits to the 
electron density data. Residues with poor fits in the final model include those residues in the 
middle of the cpβ-linker (B31Gly and C28Gly) and a terminal residue (A140Arg) where 
there was very little electron density to constrain the fit. The linkers were not designed to 
adopt a particular structure, conformational flexibility is a common characteristic of such 
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synthetic linkers. The lack of electron density for this region of the protein structure suggests 
it is dynamic and lacks significant interactions with other parts of the hemoglobin structure. 
The addition of water molecules to the model in later stages of refinement led to better 
agreement between the linker and the density map. The 157 water molecules that were added 
to the structure were validated by the density map and application of standard biophysical 
constraints (e.g., H-bonding distances, angles, etc.). Many more waters could have been 
placed, but they violated the maximum distance possible for a hydrogen bonded water 
molecule. 
 
We speculate that it may be possible to design stabilizing interactions between the linker 
residues and other elements within the protein. The location of the linker at the interface 
between cpβ-globins presents both potential problems as well as potential opportunities. 
Linker–linker interactions may be difficult or impossible to design with current 
computational design methods. The symmetry of the Hb tetramer may promote stabilizing 
complementary linker-linker interactions that favor the T state by filling the cavity where 
2,3-BPG normally binds.  
 
Validation parameters were utilized to evaluate the model as an accurate structure, supported 
by the diffraction data. These validation parameters, shown in Figure 45 were Rwork, Rfree, 
RMSD(bonds), RMSD(angles), Clashscore, and Average B. The Rwork value quantifies the 
level of agreement between the X-ray diffraction data and the crystallographic model 
(Equation 3) by relating calculated (Fcalc) and observed (Fobs) structure factors (Equation 4), 
where ‘I’ is intensity and ‘hkl’ are Miller indices. The Rfree value behaves in the same fashion 
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as Rwork, but is employed to assay accuracy of the model [25]. This is accomplished by 
comparing computed structure factors with a random batch of reflections that were excluded 
from the modeling and refinement process [25]. ‘RMSD(bonds)’ indicates root mean squared 
deviation from standard bond lengths. ‘RMSD(angles)’ indicates deviation from standard 
bond angles. ‘Clashscore’ quantifies the degree of clashing between the calculated electron 
clouds of adjacent atoms. ‘Average B’ indicates the average temperature of atoms within the 
model by averaging their individual temperatures, which are quantified by a B-factor value 
(Equation 5, where ‘u’ is the displacement from the scattering center and ‘B’ is the calculated 
B-factor value). The final model agreed very well with other published models with similar 
resolution. Comparison between values of the validation parameters for our structural model 
and the published data is presented in Figure 45. 
 
 
Figure 45. Histograms of relevant validation parameters for molecular models with similar 
resolution to the α-cpβ model.  
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(Equation 3) 
 
(Equation 4) 
 
(Equation 5) 
 
The initial Rwork and Rfree values were 0.3663 and 0.375, respectively, indicating that the 
search model was a reasonable starting structure, but significant modifications would be 
needed to make it acceptable. A lower number for both parameters is desirable as it indicates 
the degree to which the model fits the data and the level of bias that has been imposed on the 
interpretation of the data by the model. The refinement goal was an Rwork of 0.22 and an Rfree 
of 0.27, significantly lower than the starting values. After 18 rounds of manual refinement 
combined with >170 rounds of computer aided refinement, an Rwork of 0.1833 and an Rfree of 
0.2460 was achieved (Tables 8 and 9). An artificially low Rwork can be achieved by over 
fitting the model to the data, we do not believe that that is the case with our model as the Rfree 
is within acceptable limits, and the validation parameters of our structure compared very well 
to those of structures with similar resolution and number of residues. These values indicate 
that we have produced a model that very closely represents the true structure of the α-cpβ 
hemoglobin protein in complex with heme and oxygen. 
 
 Table 11. Progress of model refinement as a function of model fitting/electron density map 
refinement iterations. 
 
 
 
Initial Round 1 Round 4 Round 8 Round 90 Round 188
Rwork: 0.3663 0.2727 0.2750 0.2103 0.1870 0.1833
Rfree: 0.3753 0.3050 0.3022 0.2955 0.2610 0.2460
Description:
PDB ID: 2dn1 
w/out ligands
Trimmed 
termini
Backbone fit 
to maps
Sidechains fit 
to maps
Iterative 
revisions
Final model
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 Table 12. X-ray data collection and refinement statistics for the final α-cpβ model 
 
X-ray Data Collection and Refinement Statistics  
  data set name   α-cpβ-Hb 
 beamline   
 space group  P 21 21 21 
 resolution (Å)  28.61 - 2.72 
 no. of unique reflections  14234 (1376) 
 unit cell (Å)  a = 64.454 
   b = 79.444 
   c = 99.751 
 angle (deg)  α = 90 
   β = 90 
   γ = 90 
 completeness (%)  99.87 (98.85) 
 〈I〉/〈σ(I)〉  23.52 (5.87) 
Refinement Statistics 
 resolution reflection used (Å)  30-2.25 
 no. of protein residues in the model  587 
 no. of water molecules  286 
 R-factor(%)  0.18330 (0.2095) 
 Rfree (%)  0.2460 (0.2989) 
 rmsd for bond legths (Å)   0.0189 
 rmsd for bond angles (deg)  1.53 
 φ, ψ most favored (%)  95.63 
 φ, ψ additionally favored (%)  4.2 
 φ, ψ generously favored (%)  0 
 φ, ψ disallowed (%)  0.1 
 Wilson B-factor  47.04 
 average B-factor (Å2)  45.3 
  protein  45.2 
  ligand  38.7 
   solvent   51.7 
*Statistics for the highest-resolution shell are shown in parentheses 
 
 
The final structural model is illustrated in Figure 46. Recall that α1β2 interfacial interactions 
are essential for T state stability and optimal Hb function. A primary goal of this work was to 
establish the degree to which this interface had been perturbed by circular permutation of the 
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β-globin. Figure 47 shows the superposition of αcpβ and wtHb backbone structures with an 
overall RMSD of 2.67 Å. Though the inter-heterodimer binding affinity was greatly reduced 
by circular permutation of the β-globin (see Table 1), the crystal structure shows that the 
heterodimers still associate in a native-like tetramer. This was not unexpected given previous 
observations that α-cpβ exists predominantly in the tetramer state in solution at 
concentrations > 40 μM (see Figure 18; [11]). Sixteen heme-ligand states were identified for 
Hb structures deposited in the PDB (Table 13). Each of these was compared to the modeled 
heme-ligand state, and it was determined that the oxygen bound R-state present in PDB ID 
2dn1 most closely matched that of the model. The refined structure also shows new density 
consistent with the expected location of the linker (Figure 48). Figure 49 shows electron 
density consistent with O2 bound to the heme Fe
2+ ion. Minor changes in the binding pocket 
environment can be observed (unfilled green density), which may have an effect on ligand 
binding affinity. Figure 50 shows that the cpβ-globin termini were relocated as expected, and 
that the N-terminal Met is removed by methionine aminopeptidase (consistent with ESI-MS 
data shown in Figure). The α-globin termini remain in their wtHb orientation as shown in 
Figure 51. 
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Figure 46. Cartoon model of the final α-cpβ structural model with heme groups and ligands 
modeled in stick format. α-Globins are in red and cpβ-globins are in blue. 
 
 
 
 
Figure 47. Overlaid cartoon models of the final α-cpβ structure and wtHb. α-Globins are in 
red, cpβ-globins are in blue, and the wtHb (PDB ID: 1gzx) is in yellow, RMSD (Å): 2.67. 
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 Table 13. Example structures collected from the PDB of different R and T state configurations. 
 
  
 
 
 
 
Figure 48. Electron density and stick model of the final α-cpβ structure of the cpβ linker. The 
composite map is in blue (calculated density) and the difference map is in green (missing 
density) and red (excess density). cpβ-Globin residues, heme ligand, and oxygen ligand are 
modeled in stick form. Green polygons indicate minor unresolved model deficiencies. 
 
PDB ID Bound Ligand Resolution State (R or T) Space Group a b c α β γ
3p5q aquo met 2.00 R P41212 53.55 53.55 192.76 90 90 90
1hgb aquomet 2.10 T P21212 95.78 97.78 65.49 90 90 90
2dn3 carbonmonoxy 1.25 R P41212 53.27 53.27 189.78 90 90 90
1mko carbonmonoxy 2.18 RR2 (novel) P21212 65.53 154.57 55.27 90 90 90
1yzi carbonmonoxy 2.07 R3 P4122 61.46 61.46 174.75 90 90 90
1bbb carbonmonoxy 1.70 R2 (novel) P212121 97.5 101.5 61.1 90 90 90
1ird carbonmonoxy 1.25 P41212 53.27 53.27 190.78 90 90 90
1aby cyano met 2.60 P212121 102.54 115.17 56.7 90 90 90
2dn2 deoxy 1.25 T? P21 63.1 82.91 53.65 90 99.29 90
1hga deoxy 2.10 T P21212 95.78 97.78 65.49 90 90 90
2dn1 oxy 1.25 R P41212 53.44 53.44 191.71 90 90 90
1hho oxy 2.10 R P41212 53.7 53.7 193.8 90 90 90
1gzx oxy 2.10 T P21212A 97.05 99.5 66.11 90 90 90
1thb oxy/deoxy 1.50 T P21212 95.8 97.8 65.5 90 90 90
1hgc oxy/deoxy 2.10 T P21212 95.78 97.78 65.49 90 90 90
1bz1 deoxy 1.59 P21 63.3 83.6 53.8 90 99.4 90
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Figure 49. Structure refinement view of one cpβ-globin heme-binding pocket. The composite 
map is in blue (calculated density) and the difference map is in green (missing density) and 
red (excess density). cpβ-Globin residues, heme ligand, and oxygen ligand are modeled in 
stick form. Green polygons indicate minor unresolved model deficiencies. 
 
 
 
 
 
Figure 50. Structure refinement view of the cpβ-globin termini. The composite map is in blue 
(calculated density) and the difference map is in green (missing density) and red (excess 
density). cpβ-Globin residues and waters are modeled in stick form.  
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Figure 51. Structure refinement view of the α–globin termini. The composite map is in blue 
(calculated density) and the difference map is in green (missing density) and red (excess 
density). α–Globin residues and waters are modeled in stick form.  
 
Ligand binding data show that α-cpβ has predominantly R state character, thus, we expected 
that the protein would crystallize in an R-like conformation. Figure 52 shows the 
superposition of α-cpβ subunits with high resolution structures of the corresponding wild 
type hemoglobin subunits in R- and T-states (PDB ID: 2dn1 and 2dn2). The cpβ subunits 
show greater similarity to wt Hb R state β globins; however, the α globins in α-cpβ adopt a 
conformation that is equally similar to wt Hb R- and T- state conformations (Figure 53). 
Figure 54 indicated that the new termini in the cpβ subunit are appropriately placed to allow 
insertion of the cpβ sequence into the G-H loop of the α globin using a pair of shorter (4-5 
residue) linkers. 
67 
 
 
 
 
Figure 52. Structural homology of cpβ-globin to the oxy (R-state) and deoxy (T-state) wtHb 
structures. RMSD = root mean squared deviation, calculated with PyMol. 
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Figure 53. Structural homology of α-cpβ α-globins to the Oxy (R-state) and Deoxy (T-state) 
wtHb globin structures. RMSD = root mean squared deviation, calculated with PyMol. 
 
 
Figure 54. Cartoon model of the final α-cpβ structure, showing the potential for forming new 
covalent linkages between the α1 and cpβ1 globins, to yield a single-chain heterodimer (See 
Figure 14). 
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Conclusions: 
 
Circular permutation was achieved without significantly perturbing the tertiary structure of α-
cpβ hemoglobin. Circular permutation of the β-globin has been verified by this model, as the 
original termini clearly reside at altered positions in the structure and are connected by the 
intended linker (GSGGQGGG). The lack of the T state stabilizing interaction between α 
Lys40 and β His146 (the carboxyl terminal residue of wt β-globin) was also apparent in the 
α-cpβ model. The carboxyl group of β His146 has been incorporated into a new peptide bond 
in the engineered cpβ linker. This residue has also been pulled away from its native position 
by a distance of approximately 10 Å, rendering interaction with the amine group on α lysine 
40 impossible. The engineered cpβ-termini are readily visible in the model and are in close 
proximity (~10 Å) to the α G-H helix loop, the linkage site for the fusion of the α- and β-
globins in sc-α-cpβ. In related work from our lab, a scHb with a GAAG linker between α 
P114 and β G2 and a GGTGG between α A115 and β G155 has been successfully expressed.  
 
Modeling of the cpβ linker revealed that the middle of the linker is highly flexible and that it 
appears to lack significant stabilizing secondary structural elements (β-sheets, α-helices, salt 
bridges, or hydrogen bonds). It is interesting to note that the two cpβ linkers appear to occupy 
different three dimensional states. Optimization of the interactions between these two linkers 
could improve T state stability of the permuted Hb. The electron density map for the cpβ-
linkers is not complete in the current model. In addition, a higher resolution model will be 
needed to give better definition to side chain structures involved in interactions across the α1-
cpβ2 interface, which are critical to T state stabilization. Cyanomet and carbonmonoxy 
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isoforms of α-cpβ are more stable than the oxy-isoform crystallized in this study. 
Crystallization of these two isoforms might enable isolation of crystals that diffract to higher 
resolution than the current data set. 
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Appendix A: Catalog of crystal morphologies 
 
 
 
 
1
2
3
4
5
6
7
8
9
Clear & no crystals
Precipitated
Starfish
Clusters
Small multidomain 
Large multidomain
Small monocrystalline
Large spike monocrystalline
Plate monocrystalline
